Accuracy of Continuous Glucose Monitors During the Perioperative Period in Youth With Type 1 Diabetes
1 other identifier
observational
120
1 country
1
Brief Summary
This study is assessing the accuracy of continuous glucose monitors during surgical procedures requiring anesthesia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Aug 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 21, 2024
CompletedStudy Start
First participant enrolled
August 21, 2024
CompletedFirst Posted
Study publicly available on registry
August 28, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2025
CompletedDecember 11, 2024
December 1, 2024
1 year
August 21, 2024
December 6, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Accuracy of CGM compared to blood glucose using standard statistical methods including mean absolute relative difference (MARD).
Accuracy assessment will be completed comparing CGM glucose values to blood glucose values using standard statistical assessments.
Perioperatively (length of time will vary based on the operative procedure)
Study Arms (1)
Pediatric patients undergoing anesthesia
Pediatric patients who are undergoing a surgical procedure with anesthesia. Patients will have type 1 diabetes and be wearing a continuous glucose monitor as part of routine care.
Eligibility Criteria
All participants will have a clinical diagnosis of type 1 diabetes and be wearing a continuous glucose monitor as part of routine care.
You may qualify if:
- Participants will be 2 to 26 years of age at the time of enrollment.
- Participants will have a diagnosis of type 1 diabetes on insulin therapy and requiring close glucose monitoring during the hospitalization and the perioperative period.
- Participant currently wearing a continuous glucose monitor (for example: Dexcom G6 or G7; Freestyle Libre 2, 2 Plus, or 3; Medtronic Guardian 3 or 4; or future sensors as they become available) for home diabetes management and willing to share personal CGM data with the BDC clinical CGM account.
You may not qualify if:
- Pregnancy.
- Currently using hydroxyurea.
- A condition that the investigator determines would prevent the patient from participation.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Barbara Davis Center
Aurora, Colorado, 80045, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 21, 2024
First Posted
August 28, 2024
Study Start
August 21, 2024
Primary Completion
September 1, 2025
Study Completion
September 1, 2025
Last Updated
December 11, 2024
Record last verified: 2024-12